Mittendorf EA, Storrer CE, Shriver CE, et al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 2006;13:1085-1098. Mittendorf EA, Holmes JP, Murray JL, et al. CD4+ T cells in antitumor immunity: utility of an Ii-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009;9:71-78. Mittendorf EA, Perez SA, Tzonis P, et al. Combination immunotherapy for breast cancer patients: safety and immunological data from a phase II trial administering a HER2/neu-derived peptide vaccine (AE37+GM-CSF) sequentially or concurrently with trastuzumab in the adjuvant setting. Cancer Res 2010;70(24 Suppl):242s. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2003;8:3407-3418.